Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding Veklury, Core Product Sales Grow
Executive Summary
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.
You may also be interested in...
Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.
BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts
BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.
Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.